Cardiorenalmetabolic

Sheng Fu, MD, says the biggest barriers to managing heart failure, CKD, and obesity together aren't new drugs—they're broken transitions of care.

Worse kidney function and higher proteinuria at biopsy predicted significantly greater health care use over 2 years in patients with IgA nephropathy.

In a VESALIUS-CV subgroup analysis, evolocumab cut MACE by 29% in high-risk diabetes, reinforcing intensive LDL lowering for CV risk reduction.

After decades of neglect, malnutrition-related diabetes, or type 5, is finally getting the research, recognition, and clinical framework it demands.

ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.

The CHG index predicted CKM syndrome onset, progression, and adverse outcomes, suggesting a simple tool for risk stratification across disease stages.

Sandra Chaparro, MD, discusses using obesity medications in patients with heart failure.

MS was not linked to worse cardiovascular surgery outcomes, though routine home discharge was lower in this population.

At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.

The dual glucagon/GLP-1 receptor agonist is also being studied in the SYNCHRONIZE-2, SYNCHRONIZE-CVOT, LIVERAGE, and LIVERAGE-Cirrhosis trials.

Anne Komé, PharmD, explains that diabetes drug development is shifting to concurrent testing of metabolic effects.

ADA 2026 research showed how oral ketones, irisin, and SGLT2 inhibitors may reveal new metabolic pathways beyond glucose control.

Phase 3 data show survodutide normalized liver fat in 61% of patients with MASLD while reducing weight, visceral fat, and metabolic risk factors.

ADA 2026 data show survodutide cut visceral fat by 34% and liver fat by 63%, suggesting metabolic benefits beyond weight loss in phase 3 trials.

After FDA approval for children 6 and older, ADA data show inhaled insulin's safety and satisfaction benefits, but clinician awareness remains a key barrier.

GLP-1s, care standards updates, nutritional guidance, and AI adoption in diabetes management are just a few of the hot topics to be presented and debated.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

A newly approved inhaled insulin expands treatment options for kids with diabetes, offering an alternative to daily injections and pump systems.

Low risk stratification rates are fueling a looming MASH cost crisis, but earlier treatment access could bend the curve, said Zobair M. Younossi, MD.

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver disease screening.

An investigational coronary IVL catheter achieved high procedural success and favorable safety outcomes in patients with severely calcified CAD.

Real-world EHR study shows PREVENT equations deliver reliable CVD risk prediction despite missing data, guiding smarter outreach and recalibration.

Focal segmental glomerulosclerosis can lead to protein leakage in urine and hypertension; the condition is not considered curable at present, only manageable.

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study found.

Vutrisiran not only slowed progression to advanced heart failure in patients with ATTR-CM but also reduced mortality and MACE among those who developed advanced disease.